Study reports cyclin D1–CDK6 pathway drives senescent cell inflammation and age-related decline

A study published in Nature Aging shows that inhibiting the cyclin D1–CDK6 pathway suppresses pro-inflammatory signaling in senescent cells and mitigates age-related functional decline in mice, suggesting a novel senomorphic repurposing pathway for clinical-grade CDK4/6 inhibitors.

Researchers reported in Nature Aging that cyclin D1 (CCND1) and its kinase partner CDK6 are upregulated in nonproliferating senescent cells and actively drive the senescence-associated secretory phenotype (SASP) and interferon-stimulated gene (ISG) expression.

The study demonstrated that CCND1 and CDK6 promote DNA damage accumulation, resulting in cytoplasmic chromatin fragments that activate pro-inflammatory cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING) signaling.

In vivo experiments showed that hepatocyte-specific Ccnd1 knockout or systemic treatment with the CDK4/6 inhibitor palbociclib reduced DNA damage and inflammatory signaling in the livers of aged mice.

Furthermore, the researchers reported that palbociclib administration suppressed frailty and improved physical performance, as evaluated by rotarod latency, in aged mouse models.

While CCND1 is traditionally recognized as a promoter of cell cycle entry in proliferating cells, its paradoxical upregulation and pro-inflammatory function in non-dividing senescent cells represent a novel cell-cycle-independent path of action.

By linking CDK6 and CCND1 directly to DNA damage-induced cGAS-STING activation, the research provides a precise molecular mechanism explaining how cell cycle regulators maintain chronic, sterile age-associated inflammation (inflammaging).

The findings offer a translationally direct pathway for clinical translation by demonstrating that established, clinical-grade CDK4/6 inhibitors like palbociclib can act as senomorphics to mitigate age-related decline without requiring the clearance of senescent cells.

This research validates the conceptual viability of senomorphic strategies—which suppress the harmful secretory phenotype of senescent cells—as an alternative or complement to senolytic therapies that destroy senescent cells entirely.

The potential to repurpose clinically approved oncology drugs (such as CDK4/6 inhibitors) for age-related indications could significantly lower development barriers, shifting some industry focus toward low-dose or intermittent senomorphic regimens.

The clear therapeutic effect on liver tissue and physical performance in animal models highlights target areas for developers focused on metabolic aging, hepatoprotection, and frailty.

Preclinical studies evaluating whether other clinical-grade CDK4/6 inhibitors, such as ribociclib or abemaciclib, exhibit comparable or superior senomorphic profiles in aged tissues.

Investigator-led or proof-of-concept clinical trials testing low-dose or intermittent regimens of CDK4/6 inhibitors in humans to mitigate chronic inflammatory conditions without inducing the hematological toxicities typical of oncological dosing.